US Bancorp DE reduced its position in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 7.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 87,000 shares of the biopharmaceutical company’s stock after selling 7,100 shares during the period. US Bancorp DE owned approximately 0.08% of Juno Therapeutics worth $2,600,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the stock. BNP Paribas Arbitrage SA boosted its position in Juno Therapeutics by 40.1% in the first quarter. BNP Paribas Arbitrage SA now owns 28,481 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 8,150 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Juno Therapeutics by 2.8% in the first quarter. Bank of New York Mellon Corp now owns 262,801 shares of the biopharmaceutical company’s stock valued at $5,832,000 after buying an additional 7,165 shares during the last quarter. Capital Fund Management S.A. bought a new position in shares of Juno Therapeutics during the first quarter valued at approximately $1,087,000. DekaBank Deutsche Girozentrale bought a new position in shares of Juno Therapeutics during the first quarter valued at approximately $1,063,000. Finally, First Trust Advisors LP boosted its position in shares of Juno Therapeutics by 47.1% in the first quarter. First Trust Advisors LP now owns 1,377,667 shares of the biopharmaceutical company’s stock valued at $30,570,000 after buying an additional 440,984 shares during the last quarter. 64.60% of the stock is owned by institutional investors.
Juno Therapeutics, Inc. (JUNO) traded up 1.86% during mid-day trading on Friday, reaching $28.49. 722,929 shares of the company’s stock traded hands. The firm’s market cap is $2.99 billion. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $35.04. The firm has a 50 day moving average of $29.03 and a 200 day moving average of $24.53.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The company had revenue of $21.30 million during the quarter, compared to analyst estimates of $15.59 million. During the same quarter in the previous year, the business posted ($0.64) earnings per share. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. Analysts forecast that Juno Therapeutics, Inc. will post ($3.13) EPS for the current year.
Several research firms recently weighed in on JUNO. Vetr upgraded shares of Juno Therapeutics to a “buy” rating in a research note on Tuesday, May 23rd. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. Wedbush restated a “neutral” rating and issued a $24.00 price target on shares of Juno Therapeutics in a research note on Tuesday, June 6th. BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, June 20th. Finally, Morgan Stanley lowered their price objective on shares of Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Monday, May 8th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Juno Therapeutics presently has an average rating of “Hold” and an average price target of $30.86.
In related news, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total transaction of $262,500.00. Following the sale, the chief financial officer now directly owns 736,189 shares in the company, valued at approximately $22,085,670. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,053,500 shares of company stock worth $217,594,440. 15.26% of the stock is currently owned by corporate insiders.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
What are top analysts saying about Juno Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics Inc. and related companies.